

RECEIVED

JAN 26 2001

TECH CENTER 1800/2800

**KINDLY AMEND THE ABOVE-IDENTIFIED APPLICATION AS FOLLOWS:**

**In The Title of the Invention:**

Change the title of the invention to

-- Oligo- or Polydeoxyribonucleotides and Oligo- or Polynucleotides

Comprising Phosphate Moiety Non-Radioactively Labeled

Modified Nucleotides --

**In The Claims:**

Please amend claims 454, 455, 459, 461, 466, 476, 480, 482, 483, 487, 489, 494, 504, 508, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 533, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 561, 563, 564, 565, 566 and 567 as follows:

454. (Amended) An oligo- or polydeoxynucleotide which is complementary to a nucleic acid of interest or a portion thereof, said oligo- or polydeoxynucleotide comprising at least one modified nucleotide having the formula

Sig—PM—SM—BASE

wherein PM is a phosphate moiety, SM is a sugar moiety and BASE is a base moiety selected from the group consisting of a pyrimidine, a purine and a deazapurine, or analog thereof, said PM being attached to SM, said BASE being attached to SM, and Sig being covalently attached to PM directly or through a chemical linkage, said Sig [being a moiety capable non-radioactive detection] comprising a non-radioactive label moiety which can be directly or indirectly detected when attached to PM or when said modified nucleotide is incorporated into said oligo- or polydeoxynucleotide or when said oligo- or polydeoxynucleotide is hybridized to said complementary nucleic acid of interest or a portion thereof.


m2  
wt1

455. (Amended) The oligo- or polydeoxyribonucleotide of claim 454, wherein said Sig is or renders the nucleotide or the oligo- or polydeoxyribonucleotide self-signaling or self-indicating or self-detecting.




m3

459. (Amended) The oligo- or polydeoxyribonucleotide of claim 454, wherein said chemical linkage comprises a member selected from the group consisting of an olefinic bond at the [alpha-position] α-position relative to the point of attachment to the nucleotide, a -CH<sub>2</sub>NH- moiety, or both.

461. (Amended) The oligo- or polydeoxyribonucleotide of claim 454, wherein said chemical linkage comprises or includes an olefinic bond at the [delta-position] α-position relative to the point of attachment to the nucleotide, or any of the moieties:



m4



m5


466. (Amended) The oligo- or polydeoxyribonucleotide of claim 454, wherein Sig is selected from the group consisting of a ligand and a specific ligand binding protein [complexed with a binding protein therefor, and said binding protein is conjugated to ferritin].

m6

476. (Amended) The composition of claim 474, wherein said polypeptide is selected from the group consisting of avidin, streptavidin and [anti-Sig] anti-hapten immunoglobulin.

480. (Amended) The oligo- or polydeoxyribonucleotide of claim 478, wherein the sugar moiety of said terminal nucleotide has [hydrogen] oxygen atoms at each of the 2' and 3' positions thereof.

482. (Amended) An oligo- or polydeoxyribonucleotide which is complementary to a nucleic acid of interest or a portion thereof, said oligo- or polydeoxyribonucleotide comprising at least one modified nucleotide having the structural formula:



wherein BASE is a moiety selected from the group consisting of a pyrimidine, a purine and a deazapurine, or analog thereof, and wherein BASE is attached to the 1' position of the pentose ring from the N1 position when BASE is a pyrimidine or from the N9 position when BASE is a purine or a deazapurine;

wherein x is selected from the group consisting of H—, HO—, a mono-phosphate, a di-phosphate and a tri-phosphate;

wherein y is selected from the group consisting of H—, HO—, a mono-phosphate, a di-phosphate and a tri-phosphate;





wherein z is selected from the group consisting of H—, HO—, a mono-phosphate, a di-phosphate and a tri-phosphate; and

wherein Sig is covalently attached [to x, y or z] directly or through a chemical linkage to at least one phosphate selected from the group consisting of x, y, z, and a combination thereof, said Sig [being a moiety capable of non-radioactive detection] comprising a non-radioactive label moiety which can be directly or indirectly detected when so attached to [x, y or z] said phosphate or when said modified nucleotide is incorporated into said oligo- or polydeoxynucleotide or when said oligo- or polydeoxynucleotide is hybridized to said complementary nucleic acid of interest or a portion thereof.

Claim 483, line 2, after "oligo or" and before "self-signaling" change "polynucleotide" to -- polydeoxyribonucleotide -- .

m9 487. (Amended) The oligo- or polydeoxyribonucleotide of claim 482, wherein said chemical linkage comprises a member selected from the group consisting of an olefinic bond at the [alpha-position] α-position relative to the point of attachment to the nucleotide, a -CH<sub>2</sub>NH- moiety, or both.

489. (Amended) The oligo- or polydeoxyribonucleotide of claim 482, wherein said chemical linkage comprises or includes an olefinic bond at the [delta-position] α-position relative to x, y or z, or any of the moieties:




m11 494. (Amended) The oligo- or polydeoxyribonucleotide of claim 482, wherein Sig is selected from the group consisting of a ligand and a specific ligand binding protein [complexed with a binding protein therefor, and said binding protein is conjugated to ferritin].

m12 504. (Amended) The composition of claim 502, wherein said polypeptide is selected from the group consisting of avidin, streptavidin and [anti-Sig] anti-hapten immunoglobulin.


m13 508. (Twice Amended) The oligo- or polydeoxyribonucleotide of claim 506, wherein both y and z of said terminal nucleotide comprise [a hydrogen] an oxygen atom at each of the 3' and 2' positions thereof, respectively.

510. (Amended) The oligo- or polydexoyribonucleotide of claim 482, having the structural formula:



*M14* , wherein  $m$  and  $n$  represent integers from 0 up to about 100,000, and wherein said Sig moiety is attached to at least one of the phosphate moieties in said structural formula.

511. (Amended) An oligo- or [polyribonucleotide] polynucleotide which is complementary to a nucleic acid of interest or a portion thereof, said oligo- or polynucleotide comprising at least one [ribonucleotide] modified nucleotide having the formula



wherein PM is a phosphate moiety, SM is a sugar moiety and BASE is a moiety selected from the group consisting of a pyrimidine, a purine and a deazapurine, or analog thereof, said PM being attached to SM [at a position of SM selected from the 2', 3' and 5' positions, or combinations thereof], said BASE being attached to SM, and Sig being covalently attached to PM directly or via a chemical linkage, said Sig [being a moiety capable of non-radioactive detection] comprising a non-radioactive label moiety which can be directly or indirectly detected when attached to PM or when said modified nucleotide is incorporated into said oligo- or [polyribonucleotide] polynucleotide, or when said oligo- or polynucleotide is hybridized to said complementary nucleic acid of interest or a portion thereof, provided that when said oligo- or polynucleotide is an oligoribonucleotide or a polyribonucleotide, and when Sig is attached through a chemical linkage to a terminal PM at the 3' position of a terminal ribonucleotide, said chemical linkage is not [a cleaved 3' terminal ribonucleotide] obtained through a 2',3' vicinal oxidation of a 3' terminal ribonucleotide previously attached to said [oligo- or polyribonucleotide] oligoribonucleotide or polyribonucleotide.

512. (Amended) The oligo- or [polyribonucleotide] polynucleotide of claim 511, wherein said Sig is or renders the nucleotide or the oligo- or polynucleotide self-signaling or self-indicating or self-detecting.

Claim 513, line 1, change "polyribonucleotide" to -- polynucleotide -- .


Claim 514, line 1, change "polyribonucleotide" to -- polynucleotide -- .

Claim 515, line 1, change "polyribonucleotide" to -- polynucleotide -- .




516. (Amended) The oligo- or [polyribonucleotide] polynucleotide of claim 511, wherein said chemical linkage comprises a member selected from the group consisting of an olefinic bond at the [alpha-position] α-position relative to the point of attachment to the nucleotide, a -CH<sub>2</sub>NH- moiety, or both.

Claim 517, line 1, change "polyribonucleotide" to -- polynucleotide -- .

518. The oligo- or [polyribonucleotide] polynucleotide of claim 511, wherein said chemical linkage comprises or includes an olefinic bond at the [delta-position] α-position relative to the point of attachment to the nucleotide, or any of the moieties:



M16



Claim 519, line 1, change "polyribonucleotide" to -- polynucleotide -- .

Claim 520, line 1, change "polyribonucleotide" to -- polynucleotide -- .

Claim 521, line 1, change "polyribonucleotide" to -- polynucleotide -- .

Claim 522, line 1, change "polyribonucleotide" to -- polynucleotide -- .

M17

523. (Amended) The oligo- or [polyribonucleotide] polynucleotide of claim 511, wherein Sig is selected from the group consisting of a ligand and a specific ligand binding protein [complexed with a binding protein therefor, and said binding protein is conjugated to ferritin].

Claim 524, line 1, change "polyribonucleotide" to -- polynucleotide -- .

Claim 525, line 1, change "polyribonucleotide" to -- polynucleotide -- .

Claim 526, line 1, change "polyribonucleotide" to -- polynucleotide -- .

Claim 527, line 1, change "polyribonucleotide" to -- polynucleotide -- .

Claim 528, line 1, change "polyribonucleotide" to -- polynucleotide -- .

Claim 529, line 1, change "polyribonucleotide" to -- polynucleotide -- .

Claim 530, lines 1 and 2, change "polyribonucleotide" to -- polynucleotide -- .

Claim 531, line 1, change "polyribonucleotide" to -- polynucleotide -- .

M18

---

533. (Amended) The composition of claim 531, wherein said polypeptide is selected from the group consisting of avidin, streptavidin and [anti-Sig] anti-hapten immunoglobulin.

---

---

535. (Amended) The oligo- or [polyribonucleotide] polynucleotide of claim 511, wherein said Sig moiety is attached to a terminal [ribonucleotide] nucleotide in said oligo- or [polyribonucleotide] polynucleotide.

---

M19

536. (Amended) The oligo- or [polyribonucleotide] polynucleotide of claim 535, wherein the sugar moiety of said terminal [ribonucleotide] nucleotide has a hydrogen atom at the 2' position thereof.


537. (Amended) The oligo- or [polyribonucleotide] polynucleotide of claim 535, wherein the sugar moiety of said terminal nucleotide has [a hydrogen] an oxygen atom at each of the 2' and 3' positions thereof.

---

Claim 538, line 1, change "polyribonucleotide" to -- polynucleotide -- .



539. (Amended) An oligo- or [polyribonucleotide] polynucleotide which is complementary to a nucleic acid of interest or a portion thereof, said oligo- or polynucleotide comprising at least one modified nucleotide having the structural formula:



wherein BASE is a moiety selected from the group consisting of a pyrimidine, a purine and a deazapurine, or analog thereof, and wherein BASE is attached to the 1' position of the pentose ring from the N1 position when BASE is a pyrimidine or from the N9 position when BASE is a purine or a deazapurine;

wherein x is selected from the group consisting of H—, HO—, a mono-phosphate, a di-phosphate and a tri-phosphate;

wherein y is selected from the group consisting of H—, HO—, a mono-phosphate, a di-phosphate and a tri-phosphate;

wherein z is selected from the group consisting of H—, HO—, a mono-phosphate, a di-phosphate and a tri-phosphate; and

M20

wherein Sig is covalently attached [to x, y or z] directly or through a chemical linkage to at least one phosphate selected from the group consisting of x, y and z, and a combination thereof, said Sig [being a moiety capable of non-radioactive detection] comprising a non-radioactive label moiety which can be directly or indirectly detected when so attached to [x, y or z] said phosphate or when said modified nucleotide is incorporated into said oligo- or polynucleotide, or when said oligo- or polynucleotide is hybridized to said complementary nucleic acid of interest or a portion thereof, provided that when said oligo- or polynucleotide is an oligoribonucleotide or a polyribonucleotide and when Sig is attached through a chemical linkage to [y of] a terminal PM at the 3' position of a terminal ribonucleotide, said chemical linkage is not [a cleaved 3' terminal ribonucleotide] obtained through a 2',3' vicinal oxidation of a 3' terminal ribonucleotide previously attached to said [oligo- or polyribonucleotide] oligoribonucleotide or polyribonucleotide.

Claim 540, line 1, change "polyribonucleotide" to -- polynucleotide -- .

Claim 541, line 1, change "polyribonucleotide" to -- polynucleotide -- .





Claim 542, line 1, change "polyribonucleotide" to -- polynucleotide -- .

Claim 543, line 1, change "polyribonucleotide" to -- polynucleotide -- .

m21  
 544. (Amended) The oligo- or [polyribonucleotide] polynucleotide of claim 539,  
 wherein said chemical linkage comprises a member selected from the group  
 consisting of an olefinic bond at the [alpha-position] alpha-position relative to the point  
 of attachment to the nucleotide, a -CH<sub>2</sub>NH- moiety, or both.

Claim 545, line 1, change "polyribonucleotide" to -- polynucleotide -- .

546. (Amended) The oligo- or [polyribonucleotide] polynucleotide of claim 539,  
 wherein said chemical linkage comprises or includes an olefinic bond at the [delta-  
 position] alpha-position relative to x, y or z, or any of the moieties:



Claim 547, line 1, change "polyribonucleotide" to -- polynucleotide -- .

Claim 548, line 1, change "polyribonucleotide" to -- polynucleotide -- .

Claim 549, line 1, change "polyribonucleotide" to -- polynucleotide -- .

Claim 550, line 1, change "polyribonucleotide" to -- polynucleotide -- .

M23  
551. (Amended) The oligo- or [polyribonucleotide] polynucleotide of claim 539, wherein Sig is selected from the group consisting of a ligand and a specific ligand binding protein [complexed with a binding protein therefor, and said binding protein is conjugated to ferritin].

Claim 552, line 1, change "polyribonucleotide" to -- polynucleotide -- .

Claim 553, line 1, change "polyribonucleotide" to -- polynucleotide -- .

Claim 554, line 1, change "polyribonucleotide" to -- polynucleotide -- .

Claim 555, line 1, change "polyribonucleotide" to -- polynucleotide -- .

Claim 556, line 1, change "polyribonucleotide" to -- polynucleotide -- .

Claim 557, line 1, change "polyribonucleotide" to -- polynucleotide -- .

Claim 558, lines 1 and 2, change "polyribonucleotide" to -- polynucleotide -- in both instances.

Claim 559, line 1, change "polyribonucleotide" to -- polynucleotide -- .

M24  
561. (Amended) The composition of claim 559, wherein said polypeptide is selected from the group consisting of avidin, streptavidin and [anti-Sig] anti-hapten immunoglobulin.


Claim 563, lines 1 and 2, change "polyribonucleotide" to -- polynucleotide -- , both instances.

Claim 564, line 1, change "polyribonucleotide" to -- polynucleotide -- .

M25  
565. (Twice Amended) The oligo- or [polyribonucleotide] polynucleotide of claim 563, wherein both y and z of said terminal nucleotide comprise [a hydrogen] an oxygen atom at each of the 3' and 2' positions thereof, respectively.

Claim 566, line 1, change "polyribonucleotide" to -- polynucleotide -- .

567. (Amended) The oligo- or [polydexoxyribonucleotide] polynucleotide of claim 539, having the structural formula:



, wherein m and n represent integers from 0 up to about 100,000, and wherein said Sig moiety is attached to at least one of the phosphate moieties in said structural formula.

Cancel claims 568-575.

\*\*\*\*\*